Anjulie Quick explained that belantamab mafodotin affects corneal epithelial cells in addition to myeloma cells, leading to keratopathy and symptoms including decreased vision, dry eye, and photophobia, and outlined the ophthalmologist's critical role within the Risk Evaluation and Mitigation Strategy (REMS) program, which requires baseline eye exams prior to treatment initiation and ongoing examinations before every dose.
In this episode, Ali outlines the non-negotiable items on the first-fill consultation checklist, including baseline ECG requirements, medication review for drug interactions, and enrollment in manufacturer support programs.
In an interview with Pharmacy Times, Erin J. Walsh, PharmD, MS, RPh, discusses what sets VER-01 apart from previous cannabis-derived therapies, why it has generated significant interest in chronic pain research, and how its standardized pharmaceutical approach could shape the future of evidence-based pain management.
Cassandra Perkey, PharmD, BCOP, discusses how pharmacists support community CAR T-cell programs through SOP development, treatment planning, education, emergency preparedness, and lessons learned from treating the first patient.
Adding palbociclib to anti-HER2 and endocrine maintenance therapy provides a new treatment option for patients with HR-positive, HER2-positive metastatic breast cancer.
In 'Pharmacists at the Center: Managing REMS Education, Compliance, and Collaboration Across Care Settings,' our panel of experts delve into the following critical question:
Craig Beavers details how pharmacists coordinate Furoscix from identification through discharge—and how to build a diuresis model from scratch.
This episode, titled 'Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs,' features oncology pharmacists discussing the following critical question:
In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, explains the staffing, infrastructure, hospital partnerships, and scheduling strategies needed to safely deliver outpatient CAR T-cell therapy in a community oncology setting.
Erica Marini, PharmD, MS, BCPS, the host of "Mind the Meds," discusses the show's format, guest conversations, and upcoming episodes covering CAR T therapy and a Consortium of Multiple Sclerosis Centers Annual Meeting roundup.
Megan May, PharmD, BCOP, FHOPA, FAPO, discusses unanswered questions surrounding antibody-drug conjugate sequencing, biomarker testing, and medication safety in personalized breast cancer care.
Pharmacists boost VMAT2 success with med reviews, safe titration, AIMS monitoring, and access support—spotting tardive dyskinesia earlier.
Learn how pharmacists navigate prior authorizations, coverage, and patient education to start and sustain tardive dyskinesia treatment.
Antibody-drug conjugates, evolving HER2 guidelines, and biomarker-driven treatment decisions are transforming breast cancer care and expanding the oncology pharmacist’s role.
In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, outlines the essential teams, SOPs, financial planning, and safety protocols community oncology practices need to launch outpatient CAR T-cell therapy successfully.
Craig Beavers breaks down how Furoscix works, which patients are candidates, and what pharmacists should track once therapy begins at home.
In an interview with Pharmacy Times, Steib explains how structured monitoring, patient education, emergency protocols, and pharmacist involvement support the safe delivery of outpatient bispecific therapy.
Cherise Steib, PharmD, HDDP, discusses how bispecific therapies expand treatment options and the factors that determine whether patients are appropriate candidates for outpatient administration.
Craig Beavers explains what worsening congestion looks like clinically and why oral furosemide fails right when patients with heart failure need it most.
This week's episode tracks the growing nationwide cyclosporiasis outbreak and its link to lettuce, a new Utah pilot using artificial intelligence to authorize prescription refills, and FDA approvals in Alzheimer disease, precision oncology, and metastatic breast cancer.
In an interview with Pharmacy Times, Maksour explained how payer restrictions on prophylactic tocilizumab and the need for intensive patient and caregiver education can influence the safety and feasibility of outpatient bispecific therapy.
Pharmacists step up in menopause care by educating patients, personalizing treatment for hot flashes, and closing follow-up gaps with new FDA-approved options.
A panel of pharmacists and nurse practitioners discussed how interdisciplinary diabetes teams divide technology education, medication management, and follow-up care.
In an interview with *Pharmacy Times*, Manale Maksour, PharmD, BCOP, BCPS, explained that standardized protocols, multidisciplinary coordination, proactive supportive care, and clear escalation pathways are essential for safely managing CRS and ICANS during outpatient bispecific step-up dosing.
Compare revimumab and ziftomib dosing, food rules, tablet crushing, PPI interactions and half-life—key counseling tips to boost patient adherence.
Pharmacists compare revumenib and ziftomenib in AML—QTc thresholds, CYP3A4 interactions, acid suppression limits, and differentiation syndrome monitoring to optimize safety.
Choosing revimumab vs ziftomab in NPM1 AML depends on KMT2A status, transplant plans, drug interactions, adherence, and QTc monitoring.
Al-Ola Abdallah provided an overview of the DREAMM-7 trial, a multicenter phase 3 study in which belantamab mafodotin plus bortezomib and dexamethasone demonstrated a progression-free survival of approximately 3 years compared with 13 months for the daratumumab plus bortezomib and dexamethasone comparator arm, along with a 42% reduction in the risk of death and higher rates of minimal residual disease (MRD) negativity.
Menin inhibitors show promising AML responses—revumenib enables remissions and transplant bridging, while new combinations target KMT2A and NPM1.
The panelists discussed how BCMA-targeted therapies have rapidly evolved from last-resort options for heavily pretreated patients to agents now considered earlier in the treatment continuum, driven by their remarkable response rates, depth of response, and improving survival outcomes.
